Patient preferences for osteoporosis in Spain: A discrete choice experiment

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1947-1954

  Darba J ^a   Restovic, G ^b   Kaskens, L ^b   Balbona, M A ^c   Carbonell, A ^d   Cavero, P ^e   Jordana, M ^f   Prieto, C ^g   Molina, A ^h   Padro I ⁱ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BCN   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ HOSPITAL DEL MAR   (Spain)

Author keywords

Discrete choice experiment (DCE); Osteoporosis; Patient preferences; Willingness to pay (WTP)

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; CONFERENCE PAPER; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DISCRETE CHOICE EXPERIMENT; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; METHODOLOGY; OSTEOPOROSIS; PATIENT PREFERENCE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SELF MEDICATION; SPAIN; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CHOICE BEHAVIOR; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT PREFERENCE; SELF ADMINISTRATION; SOCIOECONOMIC FACTORS; SPAIN;

EID: 79960006999     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1382-3     Document Type: Conference Paper

References (18)

1. Bouza C, López T, Palma M, Amate JM (2007) Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry. Osteoporos Int 18(5):649-657 (Pubitemid 46525545)
2. Prevención de la osteoporosis (2009). El coste de la Desinformación del paciente. Available at: http://www.economiadelasalud. com/Ediciones/04/pdf/04-EnPortada-Prevencion.pdf. Accessed 24 February 2009
3. Vademecum España (2010) Drug tariff references to 2010. Available at: www.vademecum.es. Accessed 2 July 2010
4. Información de medicamentos autorizados en España (2006) Drug tariff references to 2006. Available at: http://www.imedicinas.com/GPTage/ Home.php. Accessed 2 July 2010
5. Guía de prescripción terapéutica (2009). Información de medicamentos autorizados en España. Available at: http://www.imedicinas.com/GPTage/Search.php?text=osteoporosis. Accessed 24 February 2009
6. Greenfield S, Kaplan S, Ware JE Jr (1985) Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 102:520-528 (Pubitemid 15109013)
7. Edworthy SM, Devins GM (1999) Improving medication adherence though patient education distinguishing between appropriate and inappropriate utilization. J Rheumatol 26:1793-1801 (Pubitemid 29367322)
8. Daltroy LH (1993) Doctor-patient communication in rheumatological disorders. Baillières Clin Rheumatol 7:221-239 (Pubitemid 23204983)
9. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medication. Arch Intern Med 165:2414-2419
10. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ et al (2008) Patients' preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 19:1029-1037
11. Fraenkel L, Gulanski B, Wittink D (2006) Patient Treatment Preferences for Osteoporosis. Arthritis Rheum 55(5):729-735 (Pubitemid 44619186)
12. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843)
13. Green W (1998) LIMDEP Version 8, Users Manual. Econometric Software Inc
14. Propper C (1995) The disutility of time spent on the United Kingdom's National Health Service waiting lists. J Hum Resour 30:677-700
15. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ et al (2009) Preferences of GPs and patients for preventive osteoporosis drug treatment. A Discrete-choice experiment Pharmacoeconomics 27(3):211-219
16. Ryan M (1999) Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation. Soc Sci Med 48:535-546 (Pubitemid 29023284)
17. San Miguel F, Ryan M, McIntosh E (2000) Applying conjoint analysis in economic evaluations: an application to menorragia. Appl Econ 32:823-833 (Pubitemid 30332713)
18. Lloyd A, McIntosh E, Price M (2005) The importance of drug adverse effects compared with seizure control for people with epilepsy. A Discrete choice experiment. Pharmacoeconomics 23(11):1167-1181 (Pubitemid 41633405)